Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-SARS-CoV-2 S2/Spike glycoprotein 2 Antibody (18H2)

Catalog #:   VVV00506 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA, Neutralization
Accession: P0DTC2
Overview

Catalog No.

VVV00506

Species reactivity

SARS-CoV-2 (2019-nCoV)

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

Spike glycoprotein, S glycoprotein, Spike protein S2, S, 2, SARS-CoV-2 (2019-nCoV)

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P0DTC2

Applications

ELISA, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

18H2

Data Image
References

Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603

Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013

Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771

Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608

Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants., PMID:40215243

Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2' site., PMID:40198676

RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaques., PMID:40159504

Membrane-targeted immunogenic compositions using exosome mimetic approach for vaccine development against SARS-CoV-2 and other pathogens., PMID:40157987

Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma., PMID:40133428

Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine., PMID:40088511

A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants., PMID:40000611

NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants., PMID:39994733

Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold., PMID:39966941

A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses., PMID:39955548

A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay., PMID:39929938

Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses., PMID:39908344

Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques., PMID:39847599

Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera., PMID:39827186

Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice., PMID:39774966

Characterization of Site-Specific N- and O-Glycopeptides from Recombinant Spike and ACE2 Glycoproteins Using LC-MS/MS Analysis., PMID:39769415

Structural Immunology of SARS-CoV-2., PMID:39731211

Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults., PMID:39723823

SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization., PMID:39621785

Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo., PMID:39621673

Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV., PMID:39589795

A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection., PMID:39548371

Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection., PMID:39516286

Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens., PMID:39337303

Discovery and characterization of a pan-betacoronavirus S2-binding antibody., PMID:39326419

Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection., PMID:39248629

A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein., PMID:39242614

Characterization of monoclonal antibodies targeting SARS-CoV-2 spike glycoprotein: Reactivity against Delta and Omicron BA.1 variants., PMID:39216601

Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens., PMID:39191724

Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters., PMID:39162540

Structure and inhibition of SARS-CoV-2 spike refolding in membranes., PMID:39146425

Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein., PMID:39125749

Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients., PMID:39122634

Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination., PMID:39094579

Evidence that the SARS-CoV-2 S protein undergoes a conformational change at the Golgi complex that leads to the formation of virus neutralising antibody binding epitopes in the S1 protein subunit., PMID:39094503

The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2., PMID:39093891

SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition., PMID:39059371

Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency., PMID:38975334

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines., PMID:38944664

Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions., PMID:38932494

Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection., PMID:38830902

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells., PMID:38807606

Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes., PMID:38805803

The Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection., PMID:38793682

Role of prior immunity in binding to spike of "future" Omicron subvariants., PMID:38782260

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-SARS-CoV-2 S2/Spike glycoprotein 2 Antibody (18H2) [VVV00506]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only